Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)

Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I) is a phase 2, randomised interventional study registered as NCT06923345 by Sixth Affiliated Hospital, Sun Yat-sen University, with a registry enrolment figure of 80 participants, started 2025-03-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: Reduced CTV; Conventional CTV. Conditions listed: Rectal Cancer; Neoadjuvant Therapies; Immune Checkpoint Therapy; Radiotherapy. Primary outcome: Complete response (CR) rate. Colorectal eligibility wording from the registry: "* Histologically confirmed rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.